[The therapeutic efficacy in Fisher syndrome].
We studied clinical courses of 15 cases of Fisher syndrome (FS) and examined therapeutic efficacy of plasma exchange (PE), immunoadsorption (IA), intravenous immune globulin (IVIg), and steroid therapy (ST). Compared with other treatments, PE and IA had shortened the peak period of the symptoms, but had not revealed the difference of the duration of illness between one another. As for PE and IA, the short-term effect was seen, but did not show the long-term effect. Though IVIg was done at the early stage, it did not shorten the peak period. So we conclude IVIg for FS to be effective not so equal as PE. However, clinical manifestations were milder in IVIg cases than PE, and there was a possibility that the symptoms of FS became mild by early treatment with Mg. Compared with Guillain-Barré syndrome, it is rare for FS to leave aftereffects and convalescence is good, so the choice of a therapy should be considered with a severity and complications.
Koyama
Kazuo
K
Department of Neurology, Yokohama-city University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Dei
Fumi
F
Koyano
Shigeru
S
Suzuki
Yume
Y
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007163:Immunosorbent Techniques; D008297:Male; D008875:Middle Aged; D019846:Miller Fisher Syndrome / Q000503:physiopathology / Q000628:therapy*; D010951:Plasma Exchange; D013256:Steroids / Q000627:therapeutic use
D016756:Immunoglobulins, Intravenous; D013256:Steroids